申请人:UNIV PITTSBURGH
公开号:WO2012033525A2
公开(公告)日:2012-03-15
Novel p53-Mdm2 antagonists that conform to Formula I or to Formula II: where the prescribed substituent groups are defined, are useful in treating or preventing cancer. In particular, the compounds and their pharmaceutical compositions are useful for treating relapsed/refractory acute myeloid and lymphoid leukemia and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas.